Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union

This interactive course will discuss the regulatory requirements within these regions, and discuss the implications of the new joint Eurasian Union regulation.

28 Feb-1 Mar 2019

GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 21 Jan

Book now

Course overview

The aim of this course is to provide an overview of recent developments in pharmaceutical regulatory affairs in Russia, the Eurasian Union and the CIS. This interactive course will discuss the regulatory requirements within these regions, and discuss the implications of the new joint Eurasian Union regulation. The focus will be on practical aspects to assist in developing your regulatory strategy for product approval in these countries and the presentations will give practical hints on the regulatory process where possible.

Benefits of attending:

  • Understand the competitive landscape of the growing markets in the CIS region
  • Discover the essential information on the latest regulations and registration procedures in the Eurasian Customs Union
  • Discuss national requirements and guidance for drug approval in the core CIS markets of Russia, Kazakhstan, Belarus, Ukraine and Azerbaijan
  • Develop your CIS Regional Submission Plan and place it within the global regulatory strategy
  • Gain practical advice from an industry expert working in the the CIS region

Why you should attend

Attending this programme will:

  • Give you the full background to the CIS pharmaceutical market
  • Ensure that you understand the full implications of the new regulations which will affect how you do business in the Eurasian Economic Union (EAEU)
  • Help clarify the document requirements and timelines of national procedures and EAEU registration procedures
  • Fully update you on the national regulations in Russia, Belarus, Kazakhstan, Ukraine and other CIS countries

Who should attend?

This seminar will be of particular interest to:

  • Anyone working in pharmaceutical regulatory affairs in this region
  • Anyone interested in an update on recent developments

Programme

Russia – competitive landscape

  • Current market and projected growth
  • Pharma-2020 and Health-2020 State programmes
  • Pricing and reimbursement
  • Patent and data protection

Clinical trials in Russia and CIS

  • Russia and CIS in global clinical research
  • Clinical trial requirements
  • Local registrations trials in Russia, CIS and the Eurasian Union

Marketing authorisations in Russia

  • Regulatory authorities in Russia
  • Key regulations governing the MAA process
  • Registration procedures
  • Application dossier requirements

CIS – regional regulatory overview

  • CIS pharmaceutical market
  • CIS regional regulation co-operation – the Eurasian Union
  • CIS regulatory barriers for Market Access

Marketing authorisations in CIS

  • New Eurasian MAA procedure
  • Common regional requirements in CIS
    - Administrative data – Translations
    - CPP
    - Dossier format
    - Local normative documents – Samples
    - Labelling
  • Country specific requirements for MAAs
    - Ukraine, Kazakhstan, Belarus, Moldova, Georgia, Armenia,
    Azerbaijan, Uzbekistan, Tajikistan, Turkmenistan, Kyrgyzstan
  • Regional regulatory strategy

Workshop – CIS regional regulatory strategy

Discussion sessions will take place throughout the two days

Presenter

Anna Harrington-Morozova

Anna Harrington-Morozova is a regulatory, drug development and external relations professional with over 20 years’ experience gained working in a Regulatory Authority, academia and industry. Anna graduated in Russia as a pharmacist. After working in the Russian Ministry of Health and the Clinical Pharmacology Department of
Moscow Medical University, she held regulatory and external relation positions in the pharmaceutical industry and CROs in Russia and the UK, including senior regulatory affairs posts in GSK,EISAI, ICON and PRA. Anna currently acts as a Scientific and Regulatory Director at Regem Consulting Ltd – a regulatory and drug development consultancy with a focus on global regulatory and drug development strategies, advocacy and registrations in emerging markets.

Book now

28 Feb-1 Mar 2019
28 Feb-1 Mar 2019 Cavendish Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 21 Jan
Enrol now

You may also be interested in

Previous customers include...

  • Abbott
  • AbbVie AG
  • ASTELLAS
  • AstraZeneca
  • Biogen
  • Cesra Arzneimittel GmbH & Co. KG
  • Ferring International Center SA
  • Ferring Pharmaceuticals FICSA
  • Gilead Sciences
  • Horus Pharma
  • LEO Pharma A/S
  • Menarini Ricerche s.p.a
  • Novo Nordisk A/S
  • PRA Health Sciences
  • RB
  • Research and Markets
  • RRG
  • Service Comptabilité
  • Vifor Pharma Ltd.

Too much information in two days

Adeline Carnet, , Service Comptabilité

Anna presented very well and gave great insights into the regulatory processes in the CIS and Russia region.

Jackie Campbell, Senior Regulatory Affairs Associate, Gilead Sciences

Very good

Dimitri Poyer, Associate Regulatory Affairs Director, ASTELLAS

Schedule too tight, better three days than two. "Small" CIS countries have not been discussed due to lack of time. More interactive discussion would be fruitful.

Gunar Hadiprono, Senior Regulatory Affairs Manager International, Cesra Arzneimittel GmbH & Co. KG

Informative course, full of content, with a knowledgeable and experienced speaker.

Jessica Bridgewater, GRA Associate, RB